SCHEMBL10147424

SCHEMBL10147424

CCOC(=O)c1ncc(-c2ccc(C)cc2C)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
KDM4E B2RXH2 4/20 0.48
HPGD P15428 4/20 0.48
LMNA P02545 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LIMK1 P53667 1/20 0.45
NPSR1 Q6W5P4 2/20 0.44
TP53 P04637 3/20 0.44
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 4/20 0.41
GAA P10253 2/20 0.41
GLA P06280 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ATM Q13315 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRB1 P18505 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31301620 0.80 TRPM8 (0.51) MAPTKDM4EHPGDLMNAMEN1
SCHEMBL25415218 0.79 MAPT (0.46) MAPTKDM4EHPGDLMNANPSR1
SCHEMBL10147434 0.77 CDC7 (0.60) MAPTKDM4EHPGDLMNAMEN1
SCHEMBL21035478 0.75 MAPT (0.53) MAPTKDM4EHPGDLMNAMEN1
SCHEMBL2180059 0.74 ALDH1A1 (0.55) MAPTKDM4EHPGDLMNAMEN1
SCHEMBL2409689 0.73 MAPT (0.46) MAPTKDM4EHPGDLMNAMEN1
SCHEMBL2095752 0.73 KDM4E (0.47) MAPTKDM4EHPGDLMNAMEN1
SCHEMBL5759200 0.72 ALDH1A1 (0.56) MAPTKDM4EHPGDLMNAKMT2A
SCHEMBL10147422 0.72 TP53 (0.41) MAPTKDM4EHPGDLMNANPSR1
SCHEMBL31579207 0.72 ALDH1A1 (0.35) MAPTKDM4EHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993556-B2 Resorcinol derivatives as HSP90 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-03-31 US disclosed
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P MAPT 84/4885KDM4E 3420/4885HPGD 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.